Bibliography

Selected Publications

Clinical

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH, et al.
Lancet Oncology 9:533-42. 2008.

A smart move against cancer for vaccinia virus.
R. Alemany (Editorial)
Lancet Oncology 9:507-8. 2008.

Immunotherapeutic potential of oncolytic virotherapy.
R. Prestwich et al. (Editorial)
Lancet Oncology 9:610-12. 2008.

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.
Liu TC et al.
Molecular Therapy 16(9):1637- 42. 2008.

Fighting fire with fire: effects of oncolytic virotherapy on underlying viral hepatitis in hepatocellular carcinoma.
T. Reid (Editorial)
Molecular Therapy 16(9):1521-23. 2008.

Preclinical

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
Lee JH et al.
Cancer Gene Therapy. 17(2):73-9. 2010.

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.
Kim JH et al.
Molecular Therapy 14(3):533-42. 2006.

A pox on your tumor.
Editorial by David A. Williams, Editor-in-Chief
Molecular Therapy 14(3):313. 2006.

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.
Thorne SH et al.
Journal of Clinical Investigation. 117(11):3350-8. 2007

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
Mastrangelo M, et al.
Cancer Gene Therapy 6: 409-422. 1998

Review & Editorials

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.
Breitbach CJ et al.
Cytokine Growth Factor Review. 21(2-3):85-9. 2010.

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.
Kirn DH and Thorne SH.
Nature Review Cancer. 9(1):64-71. 2009.

JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
Merrick AE et al.
Current Opinion in Investigational Drugs. 10(12):1372-82. 2009

Back to Top